Stock ZLAB ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Zai Lab Limited

Equities

ZLAB

US98887Q1040

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
14.22 USD +3.64% Intraday chart for Zai Lab Limited -5.26% -47.97%
Apr. 17 Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading MT
Apr. 11 Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading
MT
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities
AQ
Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024
MT
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
BU
Zai Lab Changes Record Date
MT
Zai Lab Grants Share Options, Restricted Share Units to Eligible Personnel
MT
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint
AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
BU
Bristol-Myers Squibb Therapy for Pretreated Non-Small Cell Lung Cancer Meets Primary Endpoint
MT
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BU
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases
AQ
Zai Lab Reports Lesser Loss in 2023
MT
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients
MT
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
BU
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
CI
Asian Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
MT
Asian Equities Traded in the US as American Depositary Receipts End Week Lower in Friday Trading
MT
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
BU
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate for Treatment of Solid Tumors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. News Zai Lab Limited